Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

• Status: Completed
• Trial end date: 2021-05-10
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: PF-06700841

Criteria

Inclusion Criteria:

• Diagnosis of ulcerative colitis for greater than/equal to 3 months.

• Moderate to severe active ulcerative colitis

• Inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC.

Exclusion Criteria:

• Pregnant or breastfeeding

• Clinical findings suggestive of Crohn's Disease

• History of bowel surgery within 6 months